| Item Type | Name |
|
Concept
|
Antibodies, Monoclonal
|
|
Concept
|
Antibodies, Blocking
|
|
Concept
|
Antibodies, Monoclonal, Humanized
|
|
Academic Article
|
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
|
|
Academic Article
|
Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH).
|
|
Academic Article
|
Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.
|
|
Academic Article
|
Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP).
|
|
Academic Article
|
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy.
|
|
Academic Article
|
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
|
|
Academic Article
|
First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status.
|
|
Academic Article
|
Steroid Use Independently Predicts for Poor Outcomes in Patients With Advanced NSCLC and High PD-L1 Expression Receiving First-Line Pembrolizumab Monotherapy.
|
|
Academic Article
|
Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer.
|
|
Academic Article
|
Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial.
|
|
Academic Article
|
Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable stage III non-small-cell lung cancer.
|
|
Academic Article
|
Patient-Reported Outcomes with Durvalumab With or Without Tremelimumab Versus Standard Chemotherapy as First-Line Treatment of Metastatic Non-Small-Cell Lung Cancer (MYSTIC).
|
|
Academic Article
|
Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study.
|
|
Academic Article
|
Antibody-Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade.
|
|
Academic Article
|
Pembrolizumab plus Chemotherapy in Lung Cancer.
|
|
Academic Article
|
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.
|
|
Academic Article
|
Role of cetuximab in the treatment of patients with NSCLC: are we throwing out the baby with the bath water?
|
|
Academic Article
|
Response of thymoma to cetuximab.
|
|
Academic Article
|
Development and clinical indications of cetuximab.
|
|
Academic Article
|
Predicting response of molecular targeted therapies: a still possible challenge?
|
|
Academic Article
|
Immune Checkpoint Blockade: A New Era for Non-Small Cell Lung Cancer.
|
|
Academic Article
|
Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
|
|
Academic Article
|
Reply to FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS-mutated tumours in the randomised German AIO study KRK-0306.
|
|
Academic Article
|
Risk/benefit profile of bevacizumab in metastatic colon cancer: a systematic review and meta-analysis.
|
|
Academic Article
|
Shifting From a "One Size Fits All" to a Tailored Approach for Immune-Related Adverse Events.
|
|
Academic Article
|
Should KRAS mutations be considered an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab?
|
|
Academic Article
|
Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study.
|
|
Academic Article
|
Cetuximab for colorectal cancer.
|
|
Academic Article
|
Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out.
|
|
Academic Article
|
Multiple sclerosis associated with pembrolizumab in a patient with non-small cell lung cancer.
|
|
Academic Article
|
Impact of Patient Characteristics, Prior Therapy, and Sample Type on Tumor Cell Programmed Cell Death Ligand 1 Expression in Patients with Advanced NSCLC Screened for the ATLANTIC Study.
|
|
Academic Article
|
Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial.
|
|
Academic Article
|
Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer.
|
|
Academic Article
|
RELEVENT Trial: Phase II Trial of Ramucirumab, Carboplatin, and Paclitaxel in Previously Untreated Thymic Carcinoma/B3 Thymoma With Area of Carcinoma.
|
|
Academic Article
|
Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score =50% treated with front-line pembrolizumab.
|
|
Academic Article
|
Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133).
|
|
Academic Article
|
Bevacizumab for non-small-cell lung cancer.
|
|
Academic Article
|
Cetuximab for metastatic colorectal cancer.
|
|
Academic Article
|
Immunotherapy: a new standard of care in thoracic malignancies? A summary of the European Respiratory Society research seminar of the Thoracic Oncology Assembly.
|
|
Academic Article
|
Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
|
|
Academic Article
|
Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study.
|
|
Academic Article
|
Avelumab Versus Docetaxel in Patients With Platinum-Treated Advanced NSCLC: 2-Year Follow-Up From the JAVELIN Lung 200 Phase 3 Trial.
|
|
Academic Article
|
Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189.
|
|
Academic Article
|
Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy.
|
|
Academic Article
|
Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With NSCLC and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, -189, and -407.
|
|
Academic Article
|
Tocilizumab for the treatment of immune-related adverse events: a systematic literature review and a multicentre case series.
|
|
Academic Article
|
Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial.
|
|
Academic Article
|
Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.
|
|
Academic Article
|
Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN.
|
|
Academic Article
|
Brief Report: Exploratory Analysis of Maintenance Therapy in Patients With Extensive-Stage SCLC Treated First Line With Atezolizumab Plus Carboplatin and Etoposide.
|
|
Academic Article
|
Durvalumab ± Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden.
|
|
Academic Article
|
Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Results From the CANOPY-1 Trial.
|
|
Academic Article
|
Atezolizumab Plus Carboplatin and Etoposide in Patients with Untreated Extensive-Stage Small-Cell Lung Cancer: Interim Results of the MAURIS Phase IIIb Trial.
|
|
Academic Article
|
Pembrolizumab Plus Chemotherapy for Metastatic NSCLC With Programmed Cell Death Ligand 1 Tumor Proportion Score Less Than 1%: Pooled Analysis of Outcomes After Five Years of Follow-Up.
|
|
Academic Article
|
Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: analyses of the CASPIAN phase 3 study.
|
|
Academic Article
|
Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study.
|
|
Academic Article
|
Pembrolizumab with platinum-based chemotherapy with or without epacadostat as first-line treatment for metastatic non-small cell lung cancer: a randomized, partially double-blind, placebo-controlled phase II study.
|
|
Academic Article
|
The KEYVIBE program: vibostolimab and pembrolizumab for the treatment of advanced malignancies.
|
|
Academic Article
|
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial.
|
|
Academic Article
|
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.
|